XORTX Therapeutics

XORTX is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection as well as XRx-225 which is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN).